Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
LONDON, March 22, 2016 -- APCER Life Sciences, the truly global provider of safety, medical, regulatory, and technology services, will be a major participant in the Drug Information Association’s 28th Annual EuroMeeting, taking place April 6-8, 2016, in Hamburg, Germany. The company will host a presentation in the Innovation Theatre and have a large presence in the exhibit hall of the Congress Center Hamburg.
“We are excited that we have reached the point in our company’s growth where we can support the DIA EuroMeeting at a significant level,” said Michael Britt, APCER Europe’s business unit leader and Global Head of Quality and Compliance. “The European clients that we have been serving since our founding helped us define our value proposition and build our firm into the global presence it is today.”
APCER’s presentation in the Innovation Theatre is titled “Redefining PV: From Pharmacovigilance to Patient Voice and Product Value.” It will explore how pharmacovigilance, when practiced with consistency and integrated tightly with medical affairs, can yield a rich source of real-world patient data that quantifies product value and demonstrates a competitive advantage for partnering and out-licensing deals, formulary decisions, and reimbursement rates.
APCER Life Sciences is active in the Drug Information Association around the world. In addition to the EuroMeeting, the company will be speaking at the DIA Innovations in Pharmacovigilance meeting in Mumbai, India, May 13-14, and at the 52nd DIA Annual Meeting in Philadelphia, Pennsylvania, USA, June 27-30. APCER is also exhibiting at the DIA Medical Affairs and Scientific Communications Annual Forum in Orlando, Florida, USA, this week.
About APCER Life Sciences
APCER Life Sciences is committed to improving health in partnership with its clients. It brings together safety, medical, regulatory, and technology resources from around the world to ensure that patients receive the safest, most effective therapies possible.
To learn how APCER Life Sciences works together for better health, please follow the company on Twitter, LinkedIn, and Facebook; visit www.apcerls.com; then contact APCER at one of their global offices.
Contact: Jill Notte Director, Global Marketing +1-609-436-4714
